Last quote by Irina Koffler
We view MYL as oversold due to recent uncertainty about the EpiPen franchise and management concerns, and we expect shares to recover once the company provides more visibility and guidance. Additionally, there are a number of potential catalysts that could drive share momentum over the next six months.feedback
Oct 26 2016
Irina Koffler has been quoted 4 times. The two most recent articles where Irina Koffler has been quoted are Endo International CEO steps down; Campanelli named successor and Valeant shares jump 6 percent after analyst says 'short thesis has been debunked'. Most recently, Irina Koffler was quoted as having said, “We are not surprised by this transition as De Silva's skill-set may not be helpful to the new direction of this company.”.
Take our quote verification challenge and find out !
Quotes by Irina Koffler
Sep 23 2016
We are not surprised by this transition as De Silva's skill-set may not be helpful to the new direction of this company.feedback
Aug 15 2016
Because there is now a lower likelihood of a stock collapse from another guidance miss, we think our short thesis has been debunked and are upgrading VRX to neutral with a $25 [price target] based entirely on an optimistic [sum-of-the-parts] analysis.feedback
Mar 21 2016
With the exception of a few pockets of growth like Xifaxan, consumer and contact lens, we continue to view Valeant's collection of assets as weak and eroding, and do not expect a new management team to return the business to growth.feedback
This webpage has been created by a robot: errors and absent quotes cannot be totally avoided